search
Back to results

Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction (GLADIATOR)

Primary Purpose

Heart Failure With Preserved Ejection Fraction

Status
Enrolling by invitation
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
Iohexol measurement
Geranylgeranylacetone (GGA)
Echocardiography
6-minute walking distance test
EndoPAT
Para-amino Hippuric Acid test
Electrocardiogram
Sponsored by
Amsterdam UMC, location VUmc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure With Preserved Ejection Fraction

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age≥ 50 years Patients with a diagnosis of symptomatic chronic heart failure (New York Heart Association class II or III) AND preserved systolic LV function (LV ejection fraction or LVEF ≥ 50%) documented within the last 6 months AND evidence of diastolic LV dysfunction with at least 1 out of the following 4 criteria: HFA-PEFF score ≥5 H2FPEF score ≥6 HFpEF according to the 2021 ESC HF Guidelines (NT-proBNP>125 pg/ml AND either LV mass indexed or LVMI >95 g/m2 for women and >115 g/m2 for men OR left atrial volume indexed or LAVI >34 ml/m2 OR mean e; septal/lateral < 9 cm/s) OR E/e' >13 OR TR velocity at rest >2,8m/s. Pulmonary capillary wedge pressure (PCWP) >15 mmHg and/or >25 mmHg during exercise. Exclusion Criteria: Current acute decompensated heart failure, requiring hospitalization or augmented therapy with intravenous diuretics, vasodilators, and/or inotropic drugs Acute coronary syndrome, transient ischemic attack/cerebrovascular accident, major surgery within the previous 3 months Hemoglobin <9 g/dl at screening LVEF <40% measured at any time point in the history of the patient History of mitral valve repair or replacement Presence of significant valvular disease defined as mitral valve regurgitation defined as grade ≥ 3+ MR; tricuspid valve regurgitation defined as grade ≥ 2+ TR; aortic valve disease defined as ≥ 2+ AR or > moderate AS Acute myocarditis within 3 months prior to randomization Infiltrative cardiomyopathy Genetic cardiomyopathy Severe pulmonary disease requiring home oxygen or chronic oral steroid therapy Precapillary pulmonary hypertension BMI >40 kg/m2 Estimated glomerular filtration rate (GFR) <20 ml/min or >90 ml/min History of solid organ transplantation including kidney transplantation Atrial fibrillation or atrial flutter with resting ventricular rate >110 bpm Not able to undergo the complete study protocol Doubt about compliance Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control Chronic absorption problems Proven allergy for lactose products or cow-milk. Proven allergy for Iodide-containing contrast, Iohexol or PAH. Any documented or suspected malignancy or history of malignancy within 1 year prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Currently enrolled in another investigational device or drug trial Estimated life expectancy <1 year

Sites / Locations

  • Amsterdam UMC, loc VUmc

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental arm

Placebo arm

Arm Description

Patients will receive 13 weeks of experimental treatment, followed by a 7 week wash-out period, continuing with 13 weeks of placebo as per crossover design.

Patients will receive 13 weeks of placebo treatment, followed by a 7 week wash-out period, continuing with 13 weeks of experimental treatment as per crossover design.

Outcomes

Primary Outcome Measures

Filling pressures
Changes in echocardiography determined filling pressures (E/e')?
Endothelial function
Changes in EndoPAT®-derived reactive hyperemia index (RHI)

Secondary Outcome Measures

Left atrial volumes
Changes in echogardiographic measured left atrial volume index (LAVI)
Left atrial global strain
Changes in echogardiographic measured LA global strain (LAGS)
Left atrial emptying fractions
Changes in echogardiographic LA emptying fractions. Formula: (LA maximum volume-LA minimum volume)/LA maximum volume × 100%
Left Ventricular global longitudinal strain
Changes in echocardiographically determinded LV global longitudinal strain (LGS)
Left Ventricular Myocardial relaxation
Change in echocardiographically determined myocardial relaxation (e')
Left Ventricular distensibility
Change in echocardiographically determined LV distensibility, measured by E.
Right Ventricular systolic function
Change in echocardiographically determined RV TAPSE
Pulmonary Artery Pressure
Change in echocardiographically determined PAP
Patient reported symptoms
Evaluation of symptoms using New York Heart Association class (NYHA)
Quality of life assessment
Evaluation of quality of life using the Kansas City Cariomyopathy Questionnaire
Functional capacity
Evaluation of Functional Capacity using 6-minute walking distance test (6MWD)
CRP (inflammatory biomarker)
Changes in CRP concentration in serum
Nitrosated hemoglobin (microvascular marker)
Changes in Nitrosated hemoglobin (Hb(NO)4) concentration in serum
Nitrate (microvascular marker)
Changes in nitrate concentration in serum
Endothelin-1 (microvascular marker)
Changes in Endothelin-1 concentration in serum
H2S (microvascular marker)
Changes in H2S concentration in serum
Measured Glomerular Filtration Rate (mGFR)
Changes in mGFR using Iohexol measurements in urine
Effective Renal Plasma Flow (ERPF)
Changes in ERPF using PAH-measurements in urine
Renal vascular resistance (RVR)
Changes in intrakidney hemodynamic function (Systemic Blood pressure / Renal Blood Flow)
Urine Albumine Creatinin Ratio
Changes in UACR concentration measured in urine.
Neutrophil gelatinase associated lipocalin (NGAL)
Changes in NGAL concentration measured in urine and serum
Kidney Injury marker 1 (KIM-1)
Changes in KIM-1 concentration measured in urine and serum

Full Information

First Posted
June 8, 2022
Last Updated
April 25, 2023
Sponsor
Amsterdam UMC, location VUmc
search

1. Study Identification

Unique Protocol Identification Number
NCT05672134
Brief Title
Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
Acronym
GLADIATOR
Official Title
Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 26, 2023 (Actual)
Primary Completion Date
April 26, 2025 (Anticipated)
Study Completion Date
April 26, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Amsterdam UMC, location VUmc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this double-blind randomized, placebo-controlled cross-over trial is to evaluate the effectiveness of GerenylGeranylAcetone (GGA) in patients with Heart Failure with a preserved ejection fraction. The main questions it aims to answer are: What is the effect of GGA on diastolic function? What is the effect of GGA on endothelial function? Main study tasks: Participants will be treated with either GGA or placebo for 13 weeks. After this they will have a break (wash-out) period for 6 weeks and then cross over to the other study arm. Cardiac function will be measured using echocardiogram in all participants Renal measurements and endothelial measurements will be performed on the participants. Participants will perform a 5 minute walking distance test for functional capacity. Participants will fill out questionnaires to score signs & symptoms. Researchers will compare the patients to themselves to see if the drug improves diastolic- and endothelial function.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure With Preserved Ejection Fraction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Model Description
crossover multi-centre, double-blind, randomized control trial.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental arm
Arm Type
Experimental
Arm Description
Patients will receive 13 weeks of experimental treatment, followed by a 7 week wash-out period, continuing with 13 weeks of placebo as per crossover design.
Arm Title
Placebo arm
Arm Type
Placebo Comparator
Arm Description
Patients will receive 13 weeks of placebo treatment, followed by a 7 week wash-out period, continuing with 13 weeks of experimental treatment as per crossover design.
Intervention Type
Diagnostic Test
Intervention Name(s)
Iohexol measurement
Intervention Description
Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
Intervention Type
Drug
Intervention Name(s)
Geranylgeranylacetone (GGA)
Intervention Description
13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
Intervention Type
Diagnostic Test
Intervention Name(s)
Echocardiography
Intervention Description
The investigators will perform echocardiography to find changes in cardiac function.
Intervention Type
Diagnostic Test
Intervention Name(s)
6-minute walking distance test
Intervention Description
6 minute walking distance test to compare exercise tolerance in participants.
Intervention Type
Diagnostic Test
Intervention Name(s)
EndoPAT
Intervention Description
Use of EndoPAT to measure endothelial function.
Intervention Type
Diagnostic Test
Intervention Name(s)
Para-amino Hippuric Acid test
Intervention Description
PAH-measurement to measure ERPF.
Intervention Type
Diagnostic Test
Intervention Name(s)
Electrocardiogram
Intervention Description
12-lead Electrocardiogram
Primary Outcome Measure Information:
Title
Filling pressures
Description
Changes in echocardiography determined filling pressures (E/e')?
Time Frame
after 13 weeks of treatment
Title
Endothelial function
Description
Changes in EndoPAT®-derived reactive hyperemia index (RHI)
Time Frame
after 13 weeks of treatment
Secondary Outcome Measure Information:
Title
Left atrial volumes
Description
Changes in echogardiographic measured left atrial volume index (LAVI)
Time Frame
After 13 weeks of treatment
Title
Left atrial global strain
Description
Changes in echogardiographic measured LA global strain (LAGS)
Time Frame
After 13 weeks of treatment
Title
Left atrial emptying fractions
Description
Changes in echogardiographic LA emptying fractions. Formula: (LA maximum volume-LA minimum volume)/LA maximum volume × 100%
Time Frame
After 13 weeks of treatment.
Title
Left Ventricular global longitudinal strain
Description
Changes in echocardiographically determinded LV global longitudinal strain (LGS)
Time Frame
Ater 13 weeks of treatment
Title
Left Ventricular Myocardial relaxation
Description
Change in echocardiographically determined myocardial relaxation (e')
Time Frame
Ater 13 weeks of treatment
Title
Left Ventricular distensibility
Description
Change in echocardiographically determined LV distensibility, measured by E.
Time Frame
After 13 weeks of treatment
Title
Right Ventricular systolic function
Description
Change in echocardiographically determined RV TAPSE
Time Frame
After 13 weeks of treatment
Title
Pulmonary Artery Pressure
Description
Change in echocardiographically determined PAP
Time Frame
After 13 weeks of treatment
Title
Patient reported symptoms
Description
Evaluation of symptoms using New York Heart Association class (NYHA)
Time Frame
After 13 weeks of treatment
Title
Quality of life assessment
Description
Evaluation of quality of life using the Kansas City Cariomyopathy Questionnaire
Time Frame
After 13 weeks of treatment.
Title
Functional capacity
Description
Evaluation of Functional Capacity using 6-minute walking distance test (6MWD)
Time Frame
After 13 weeks of treatment.
Title
CRP (inflammatory biomarker)
Description
Changes in CRP concentration in serum
Time Frame
After 13 weeks of treatment
Title
Nitrosated hemoglobin (microvascular marker)
Description
Changes in Nitrosated hemoglobin (Hb(NO)4) concentration in serum
Time Frame
After 13 weeks of treatment
Title
Nitrate (microvascular marker)
Description
Changes in nitrate concentration in serum
Time Frame
After 13 weeks of treatment
Title
Endothelin-1 (microvascular marker)
Description
Changes in Endothelin-1 concentration in serum
Time Frame
After 13 weeks of treatment
Title
H2S (microvascular marker)
Description
Changes in H2S concentration in serum
Time Frame
After 13 weeks of treatment
Title
Measured Glomerular Filtration Rate (mGFR)
Description
Changes in mGFR using Iohexol measurements in urine
Time Frame
After 13 weeks of treatment
Title
Effective Renal Plasma Flow (ERPF)
Description
Changes in ERPF using PAH-measurements in urine
Time Frame
After 13 weeks of treatment
Title
Renal vascular resistance (RVR)
Description
Changes in intrakidney hemodynamic function (Systemic Blood pressure / Renal Blood Flow)
Time Frame
After 13 weeks of treatment
Title
Urine Albumine Creatinin Ratio
Description
Changes in UACR concentration measured in urine.
Time Frame
After 13 weeks of treatment
Title
Neutrophil gelatinase associated lipocalin (NGAL)
Description
Changes in NGAL concentration measured in urine and serum
Time Frame
After 13 weeks of treatment
Title
Kidney Injury marker 1 (KIM-1)
Description
Changes in KIM-1 concentration measured in urine and serum
Time Frame
After 13 weeks of treatment
Other Pre-specified Outcome Measures:
Title
N-terminal pro Brain Natriuretic Peptide (NT-proBNP)
Description
Changes in NT-proBNP measured in serum
Time Frame
After 13 weeks of treatment
Title
Troponin T
Description
Changes in Troponin T measured in serum
Time Frame
After 13 weeks of treatment
Title
Clinical events
Description
Comparison of the frequency of a combined safety endpoint of death, myocardial infarction and heart failure hospitalization
Time Frame
After 13 weeks of treatment
Title
Serious Adverse Events (SAE's)
Description
Comparison of the frequency of Serious Adverse Events between both groups.
Time Frame
After 13 weeks of treatment.
Title
Treatment Emergent Adverse Events (TEAE's)
Description
Comparison of the frequency of Treatment Emergent Adverse Events between both groups.
Time Frame
After 13 weeks of treatment.
Title
Adverse events of specific interest (AESI's)
Description
Comparison of the frequency of Adverse events of specific interest between both groups.
Time Frame
After 13 weeks of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age≥ 50 years Patients with a diagnosis of symptomatic chronic heart failure (New York Heart Association class II or III) AND preserved systolic LV function (LV ejection fraction or LVEF ≥ 50%) documented within the last 6 months AND evidence of diastolic LV dysfunction with at least 1 out of the following 4 criteria: HFA-PEFF score ≥5 H2FPEF score ≥6 HFpEF according to the 2021 ESC HF Guidelines (NT-proBNP>125 pg/ml AND either LV mass indexed or LVMI >95 g/m2 for women and >115 g/m2 for men OR left atrial volume indexed or LAVI >34 ml/m2 OR mean e; septal/lateral < 9 cm/s) OR E/e' >13 OR TR velocity at rest >2,8m/s. Pulmonary capillary wedge pressure (PCWP) >15 mmHg and/or >25 mmHg during exercise. Exclusion Criteria: Current acute decompensated heart failure, requiring hospitalization or augmented therapy with intravenous diuretics, vasodilators, and/or inotropic drugs Acute coronary syndrome, transient ischemic attack/cerebrovascular accident, major surgery within the previous 3 months Hemoglobin <9 g/dl at screening LVEF <40% measured at any time point in the history of the patient History of mitral valve repair or replacement Presence of significant valvular disease defined as mitral valve regurgitation defined as grade ≥ 3+ MR; tricuspid valve regurgitation defined as grade ≥ 2+ TR; aortic valve disease defined as ≥ 2+ AR or > moderate AS Acute myocarditis within 3 months prior to randomization Infiltrative cardiomyopathy Genetic cardiomyopathy Severe pulmonary disease requiring home oxygen or chronic oral steroid therapy Precapillary pulmonary hypertension BMI >40 kg/m2 Estimated glomerular filtration rate (GFR) <20 ml/min or >90 ml/min History of solid organ transplantation including kidney transplantation Atrial fibrillation or atrial flutter with resting ventricular rate >110 bpm Not able to undergo the complete study protocol Doubt about compliance Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control Chronic absorption problems Proven allergy for lactose products or cow-milk. Proven allergy for Iodide-containing contrast, Iohexol or PAH. Any documented or suspected malignancy or history of malignancy within 1 year prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Currently enrolled in another investigational device or drug trial Estimated life expectancy <1 year
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Louis Handoko, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Adriaan Voors, MD, PhD
Organizational Affiliation
University Medical Center Groningen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Loek van Heerebeek, MD, PhD
Organizational Affiliation
Onze Lieve Vrouwe Gasthuis, Amsterdam
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amsterdam UMC, loc VUmc
City
Amsterdam
State/Province
Noord-Holland
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction

We'll reach out to this number within 24 hrs